Investors / United States / Logos Capital
Logos Capital
Venture capital · San Francisco, CA, United States · North America
Logos Capital is an investment firm focused on the biotechnology sector, conducting research on both private and public companies. It uses a proprietary data science platform, Logos Analytics, to model and analyze clinical data in support of its investment decisions.
Invests inHealthcare & Biotech
In its own wordsbiotechnologyhealthcaretherapeuticslife sciencesdata sciencepublic markets
Your fit with Logos Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsLogos Capital lists 13 checked portfolio companies on its own site and is named in 13 funding rounds. Its most frequent entry is Series A, 42% of the companies with a known first round. Its largest themes are Healthcare & Biotech (56%), Education (13%) and Industrial & Manufacturing (13%). 92% of its companies are based in United States. It invests most often alongside RA Capital, Casdin Capital and Forbion.
Counts come from funding rounds that name Logos Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundLogos Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 8% |
| Seed | 8% |
| Series A | 42% |
| Series B | 25% |
| Growth | 17% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 1 | 0 |
| '25 | 5 | 0 |
| '26 | 7 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 93th | 8 rounds in 12 months |
| Early stage | 56th | 17% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 87th | 56% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 6 |
| Casdin Capital | 3 |
| Forbion | 3 |
| Frazier Life Sciences | 3 |
| ARCH Venture Partners | 2 |
| Foresite Capital | 2 |
| GV | 2 |
| General Atlantic | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 56% | 15% |
| Education | 13% | 7% |
| Industrial & Manufacturing | 13% | 7% |
| Fintech | 6% | 12% |
| Robotics & Hardware | 6% | 1% |
| AI & Machine Learning | 6% | 18% |
Co-investor network
who it backs companies with, and who they back togetherCompare Logos Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Logos Capital| Date | Company | Stage |
|---|---|---|
| 30 Sept 2026 | Pre-Seed | |
| 16 Sept 2026 | Series A | |
| 23 Jun 2026 | Series A | |
| 26 Mar 2026 | Series B | |
| 11 Mar 2026 | Round | |
| 12 Feb 2026 | Series A | |
| 8 Jan 2026 | Series B | |
| 15 Dec 2025 | Series C+ |
Round details for Logos Capital
Amounts, full round histories and every co-investor in Logos Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alva Energy is adding 10 gigawatts to America's nuclear fleet by rewriting the economics of nuclear deployment to deliver gigawatts of clean power in years, not decades. | EducationIndustrial & Manufacturing | Feb 2026Series A | Funding round | |
| Beacon Biosignals uses AI-powered technology to accelerate drug development and power home sleep testing diagnostics | Healthcare & Biotech | Nov 2025Series B | Funding round | |
| Boundless Bio develops therapies for patients with intractable oncogene amplified cancers. | Healthcare & Biotech | Jun 2026Series A | Funding round | |
| Diagonal Therapeutics develops clustering antibodies to correct the root cause of genetic diseases | Healthcare & Biotech | Jan 2026Series B | Funding round | |
| Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases | Healthcare & Biotech | Oct 2025Series A | Funding round | |
| Longeveron is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. | Healthcare & Biotech | Mar 2026Round | Funding round | |
| Maze Therapeutics is developing breakthrough precision medicines for common diseases with large unmet medical needs | Healthcare & Biotech | Dec 2024Series C+ | Funding round | |
| Pathwork is the AI platform built for the distribution side of insurance, automating how life and health policies are sold, placed, and retained. | FintechHealthcare & Biotech | Sept 2025Seed | Funding round | |
| Pinnacle Medicines develops oral therapies using peptides to improve how patients live with chronic diseases. | Healthcare & Biotech | Mar 2026Series B | Funding round | |
| The company provides computing services using solar power at the point of generation | EducationIndustrial & Manufacturing | Sept 2026Series A | Funding round | |
| Tangent Robotics builds dexterous robot hands and learns skilled control policies for them | Robotics & HardwareAI & Machine Learning | Sept 2026Pre-Seed | Funding round | |
| Verdiva Bio is developing next-generation medicines to help people living with obesity, cardiometabolic diseases, and related conditions achieve better health outcomes | Healthcare & Biotech | Jan 2025Series A | Funding round | |
| Vor Biopharma is advancing therapies that aim to correct autoimmune disease biology, moving beyond symptom control toward lasting improvement. | Healthcare & Biotech | Dec 2025Series C+ | Funding round |
About this data
site last read 11 Nov 2026- Site
- logoscapital.com
- Last read
- 11 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 3 Dec 2024
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Logos Capital's profile as data
Pull Logos Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/logoscapital.com
# also
GET /v1/firms/logoscapital.com/portfolio
GET /v1/firms/logoscapital.com/coinvestors
GET /v1/firms/logoscapital.com/news